Hommer D W, Pickar D, Crawley J N, Weingartner H, Paul S M
Ann N Y Acad Sci. 1985;448:542-52. doi: 10.1111/j.1749-6632.1985.tb29947.x.
Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide, a cholecystokinin-like peptide, in a placebo-controlled, double-blind, crossover study. Ceruletide or placebo was administered intramuscularly twice a day for 4 consecutive days while patients were maintained on a constant dose of fluphenazine. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo and ceruletide administration. To further characterize ceruletide actions we also administered it to seven normal volunteers and evaluated its effects on cognition and mood. Volunteers were administered ceruletide (0.3 micrograms/kg or 0.6 micrograms/kg) or saline placebo intramuscularly. Ceruletide had no effects on recent or remote memory or attention, but the higher dose did cause a significant increase in fatigue. These results suggest that although CCK-like peptides lack antipsychotic or cognitive effects they do induce mild sedation. This sedation may be part of a "satiety-like" state induced by peripheral administration of CCK.
在一项安慰剂对照、双盲、交叉研究中，对8例抗神经阻滞剂的精神分裂症患者使用了一种胆囊收缩素样肽——蛙皮素进行治疗。在患者维持恒定剂量氟奋乃静的同时，每天两次肌肉注射蛙皮素或安慰剂，连续4天。在给予安慰剂和蛙皮素的期间，精神分裂症的阳性或阴性症状均无变化。为了进一步明确蛙皮素的作用，我们还将其给予7名正常志愿者，并评估其对认知和情绪的影响。志愿者肌肉注射蛙皮素（0.3微克/千克或0.6微克/千克）或生理盐水安慰剂。蛙皮素对近期或远期记忆以及注意力均无影响，但较高剂量确实导致疲劳显著增加。这些结果表明，尽管胆囊收缩素样肽缺乏抗精神病或认知作用，但它们确实会引起轻度镇静。这种镇静可能是外周给予胆囊收缩素所诱导的“饱腹感样”状态的一部分。
